These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 23857604

  • 21. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
    Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.
    Mol Cancer Ther; 2015 Jul; 14(7):1614-24. PubMed ID: 25931519
    [Abstract] [Full Text] [Related]

  • 22. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
    Nakazawa T, Murakami T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, Park YS, Motoyama Y, Tsujimura T, Wakabayashi T, Nakase H.
    Anticancer Res; 2020 Jun; 40(6):3231-3237. PubMed ID: 32487617
    [Abstract] [Full Text] [Related]

  • 23. Formation of EGFRwt/EGFRvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy.
    Jahnke K, Struve N, Hofmann D, Gote MJ, Bach M, Kriegs M, Hausmann M.
    Nanoscale; 2024 Aug 15; 16(32):15240-15255. PubMed ID: 39073345
    [Abstract] [Full Text] [Related]

  • 24. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.
    J Hematol Oncol; 2013 May 09; 6():33. PubMed ID: 23656794
    [Abstract] [Full Text] [Related]

  • 25. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
    Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB.
    Mol Cancer Ther; 2016 Apr 09; 15(4):661-9. PubMed ID: 26846818
    [Abstract] [Full Text] [Related]

  • 26. EGFRvIII as a promising target for antibody-based brain tumor therapy.
    Kuan CT, Wikstrand CJ, Bigner DD.
    Brain Tumor Pathol; 2000 Apr 09; 17(2):71-8. PubMed ID: 11210174
    [Abstract] [Full Text] [Related]

  • 27. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H.
    Biomed Pharmacother; 2019 May 09; 113():108734. PubMed ID: 30849636
    [Abstract] [Full Text] [Related]

  • 28. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB.
    Neuro Oncol; 2011 Mar 09; 13(3):324-33. PubMed ID: 21149254
    [Abstract] [Full Text] [Related]

  • 29. Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch.
    Puliyappadamba VT, Chakraborty S, Chauncey SS, Li L, Hatanpaa KJ, Mickey B, Noorani S, Shu HK, Burma S, Boothman DA, Habib AA.
    Cell Rep; 2013 Aug 29; 4(4):764-75. PubMed ID: 23972990
    [Abstract] [Full Text] [Related]

  • 30. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J, Yan J, Liu B.
    Cancer Lett; 2017 Sep 10; 403():224-230. PubMed ID: 28649003
    [Abstract] [Full Text] [Related]

  • 31. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
    Liu X, Dong C, Shi J, Ma T, Jin Z, Jia B, Liu Z, Shen L, Wang F.
    Oncotarget; 2017 Jan 24; 8(4):6364-6375. PubMed ID: 28031526
    [Abstract] [Full Text] [Related]

  • 32. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
    Li L, Puliyappadamba VT, Chakraborty S, Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P, Burma S, Boothman DA, Habib AA.
    Oncogene; 2015 Jan 02; 34(1):129-134. PubMed ID: 24362532
    [Abstract] [Full Text] [Related]

  • 33. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
    Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.
    Hum Gene Ther; 2012 Oct 02; 23(10):1043-53. PubMed ID: 22780919
    [Abstract] [Full Text] [Related]

  • 34. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma.
    Balyasnikova IV, Ferguson SD, Sengupta S, Han Y, Lesniak MS.
    PLoS One; 2010 Mar 18; 5(3):e9750. PubMed ID: 20305783
    [Abstract] [Full Text] [Related]

  • 35. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L.
    Oncotarget; 2015 Nov 10; 6(35):37570-87. PubMed ID: 26461476
    [Abstract] [Full Text] [Related]

  • 36. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
    Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV.
    Sci Transl Med; 2015 Feb 18; 7(275):275ra22. PubMed ID: 25696001
    [Abstract] [Full Text] [Related]

  • 37. EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition.
    Jutten B, Keulers TG, Peeters HJM, Schaaf MBE, Savelkouls KGM, Compter I, Clarijs R, Schijns OEMG, Ackermans L, Teernstra OPM, Zonneveld MI, Colaris RME, Dubois L, Vooijs MA, Bussink J, Sotelo J, Theys J, Lammering G, Rouschop KMA.
    Autophagy; 2018 Feb 18; 14(2):283-295. PubMed ID: 29377763
    [Abstract] [Full Text] [Related]

  • 38. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S.
    Clin Cancer Res; 2019 Dec 15; 25(24):7594-7608. PubMed ID: 31540977
    [Abstract] [Full Text] [Related]

  • 39. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, Motoyama Y, Park YS, Tsujimura T, Wakabayashi T, Nakase H.
    Cells; 2020 Apr 16; 9(4):. PubMed ID: 32316275
    [Abstract] [Full Text] [Related]

  • 40. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.
    Mol Cancer Ther; 2009 Jul 16; 8(7):1751-60. PubMed ID: 19584231
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.